Business
Clover Announces Additional Positive U.S. Phase I Clinical Data for RSV Re-Vaccination in Older Adults
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced additional positive data from a Phase I clinical trial in the U.S. evaluating re-vaccination with the company's RSV PreF vaccine candidate (SCB-1019) compared head-to-head versus GSK's RSV vaccine (AREXVY) in older adults that previously received AREXVY at least 2 seasons
About this update from Clover Biopharmaceuticals Ltd.
[{"type":"text","content":"-- Additional data from RSV re-vaccination trial demonstrates trend of approximately 60-80% higher RSV neutralizing antibodies (nAbs) for Clover's RSV vaccine compared head-to-head versus AREXVY (GSK) in older adults who previously received an initial dose of AREXVY --","length":273,"tagName":"p","attribs":{}},{"type":"text","content":"-- Re-vaccination with Clover's RSV vaccine boosted RSV nAbs to approximately 120-135% of the peak levels observed after an initial dose of AREXVY (cross-trial comparison) --","length":178,"tagName":"p","attribs":{}},{"type":"text","content":"-- Results further strengthen profile of potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection --","length":235,"tagName":"p","attribs":{}},{"type":"text","content":"SHANGHAI, March 24, 2026 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced additional positive data from a Phase I clinical trial in the U.S. evaluating re-vaccination with the company's RSV PreF vaccine candidate (SCB-1019) compared head-to-head versus GSK's RSV vaccine (AREXVY) in older adults that previously received AREXVY at least 2 seasons prior to enrolling. The results announced today are from 62 participants, whereas the results announced in October 2025 were from 34 participants.","length":695,"tagName":"p"},{"type":"text","content":""These additional clinical data in nearly double the number of subjects compared to the prior analysis re-affirm our differentiated ability to re-vaccinate older adults previously receiving an approved RSV vaccine, further strengthening the potential best-in-class profile for our RSV+hMPV±PIV3 combination vaccine candidates," said Joshua Liang, Chief Executive Officer & Board Director of Clover. "While currently approved protein-based RSV vaccines are safe & effective, critical gaps persist globally, including (1) the inability to prevent significant respiratory disease burden caused by other viruses related to RSV such as human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3) and (...